Endeavour Vision is a venture capital and private equity firm investing in growth-stage medical technology and digital health companies that is headquartered in Geneva, Switzerland and was founded in 2000 by Bernard Vogel, Damien Tappy, and Sven Lingjaerde.
Notable investments made by Endeavour Vision include: Nuvaira, Palares Medical, V-Wave, Relievant Medsystems, Vertiflex, Medartis, Symetis, VentureMed Group, EndoStim, Chrono Therapeutics, ReShape Lifesciences, Inofocus Neuromedical, Sophia, PneumRx, CeQur, and Endocart Medical Technologies.
On March 22, 2016 Endeavour Vision announced raising a venture capital fund with $275 million (€250 million) in funding that will focus on investing in medical technology and digital health companies. The fund was oversubscribed and had an initial funding target of $175 million (€150 million). The firm plans on using the fund to invest between €10 million and €20 million per investment in companies that have received regulatory approval for their products and services in the United States and/or Europe. The president, managing partner, and co-founder of Endeavour Vision, Damien Tappy made the follow statement regarding why the fund will focus on healthcare technology companies:
The big trend that everybody is talking about is the combination of digital health into medical devices.The way we consume medicine in 10 years will not be the same. It's going to be driven by the combination of IT, data, Internet with medical devices. That's a huge opportunity; I personally believe it's as big as when the Internet came on in 2000.
A business intelligence company offering an artificially intelligent analytics web-based software platform .
CeQur is a company known for developing drug delivery devices for patients with type 2 diabetes
Gynesonics develops an ablatian device for uterine fibroids.
Endeavour Vision closes $275M dedicated med tech, digital health fund
March 22, 2016